Richard Klausner

Insider Reports History

Identity 1 identity field
Location
San Diego, CA
SEC source record 1 source field
Owner filing signature
/s/ Charles Newton, as Attorney-in-Fact
Source evidence 1 source field
Transaction evidence
Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Richard Klausner

Form 4 holding Director

Lyell Immunopharma, Inc.

Security class
Option (right to buy)
Shares / value
130,000
Estimated value
Report date
14 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Richard Klausner

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .